Old Web
English
Sign In
Acemap
>
authorDetail
>
Paul Stendahl Dy
Paul Stendahl Dy
Oncology
Internal medicine
Trabectedin
Pathology
Phases of clinical research
2
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].
2020
Journal of Clinical Oncology
Erlinda M. Gordon
Victoria S. Chua-Alcala
Katherine K. Kim
Paul Stendahl Dy
Micaela Kristina Paz
Nicole Angel
Ania Moradkhani
Doris Quon
Steven G. Wong
Omid Jafari
Sant P. Chawla
Show All
Source
Cite
Save
Citations (1)
The TNT protocol: A phase II study using talimogene laherparepvec (TVEC), nivolumab (N) and trabectedin (T) as first, second/third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
2020
Journal of Clinical Oncology
Sant P. Chawla
Victoria S Chua
Katherine K. Kim
Paul Stendahl Dy
Micaela Kristina Paz
Nicole Angel
Kelly Wang
Ania Moradkhani
Doris Quon
Steven G. Wong
Omid Jafari
Erlinda M. Gordon
Show All
Source
Cite
Save
Citations (2)
1
map